Israeli Immunotherapy Company Granted US Patent
Vaxil Bio U.S. Patent # 10,245,309 provides broad protection for treating pathogenic infections using vaccines based on a pathogen’s signal peptides
An Israeli immunotherapy company announced that it has obtained an additional U.S. Patent for anti-infective vaccine platforms.
Vaxil Bio has been granted U.S. Patent # 10,245,309 entitled Antigen-specific multi- epitope-based anti-infective vaccines, which ‘provides broad protection for treating pathogenic infections using vaccines based on a pathogen’s signal peptides, or T-cell populations enriched using these peptides.’
Vaxil’s patent portfolio is segmented into 3 families, consisting of 6 issued and 10 pending patents.
Vaxil exploits the unique properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.
Vaxil’s lead product ImMucin™ successfully completed a Phase 1/2 clinical trial in multiple myeloma and received orphan drug status from the FDA and EMA.
The company is also developing a tuberculosis vaccine/treatment that has demonstrated promising preliminary results with further preclinical evaluation underway at a top US academic and research institution.
Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.
These signal peptide domains are identified by VaxHit™, Vaxil’s proprietary bioinformatic approach.
These SPs induce a robust T- and B-cell response across wide and varied HLA subtypes, while acting as true, universal neoantigens. The peptide platform targets these cells by “educating” or specifically activating the immune system to recognize and attack the affected cells.
In addition, Vaxil’s mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells.
Moreover, Vaxil’s ImMucin targets the SP domain of the MUC1 cancer antigen.
In the Phase I/II clinical study involving 15 MM patients, ImMucin induced a strong and specific response of both CD4+ and CD8+ T-cells in all patients, coupled with an antibody response in ~66% (10/15) of the patients.
This is important since MUC1 is the 2nd most promising cancer antigen, and it is expressed by over 90 percent of tumor types, says the National Cancer Insitute.
David Goren, Vaxil’s Chief Executive Officer commented: “This new U.S. patent adds to and strengthens our already robust IP portfolio and we will continue to work to further broaden this portfolio.”